FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nashington,	D.C. 20549
-------------	------------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Gould Robert J</u>				2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]							(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) Note					
(Last)	`	First) HERAPEUTICS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023]	below)	(give title erim Presido	Other (abelow) ent & CEO	specify
26 LANDSDOWNE STREET				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)	IDGE M	1A	02139												iled by One R iled by More ti 1		
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication											
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								ed to									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)				Execution		Date,	Code (Ins	Transaction Dispose Code (Instr. 5)		rities Acquired (A) o ed Of (D) (Instr. 3, 4 a		Benefici Owned F	es For ally (D) Following (I) (I	Ownership orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	V Amo	ount	(A) o (D)	Price	Reported Transact (Instr. 3	tion(s)		(Instr. 4)		
		T							uired, Dis s, options					Owned	,	,	<u> </u>
Derivative Conversion Date Executi Security or Exercise (Month/Day/Year) if any		3A. Deem Execution if any (Month/Da	Date, Transaction Code (Instr.					6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expirati Date	ion	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$3.16	06/27/2023			A		30,000		(1)	06/26/20	033	Common Stock	30,000	\$0	30,000	D	

Explanation of Responses:

1. This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

/s/ Greg Tourangeau, as attorney-in-fact for Robert J.

06/29/2023

Gould

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.